Your browser is no longer supported. Please, upgrade your browser.
Settings
CWBR CohBar, Inc. daily Stock Chart
CWBR [NASD]
CohBar, Inc.
Index- P/E- EPS (ttm)-0.36 Insider Own32.85% Shs Outstand44.91M Perf Week-2.52%
Market Cap69.61M Forward P/E- EPS next Y- Insider Trans- Shs Float28.77M Perf Month-13.89%
Income-15.00M PEG- EPS next Q- Inst Own9.50% Short Float7.50% Perf Quarter-36.99%
Sales- P/S- EPS this Y-45.10% Inst Trans-0.19% Short Ratio14.79 Perf Half Y-62.01%
Book/sh0.38 P/B4.08 EPS next Y- ROA-62.30% Target Price- Perf Year-72.12%
Cash/sh0.43 P/C3.57 EPS next 5Y- ROE-76.00% 52W Range1.52 - 7.40 Perf YTD-50.16%
Dividend- P/FCF- EPS past 5Y-41.30% ROI- 52W High-79.05% Beta1.19
Dividend %- Quick Ratio15.50 Sales past 5Y- Gross Margin- 52W Low1.97% ATR0.14
Employees12 Current Ratio15.50 Sales Q/Q- Oper. Margin- RSI (14)39.27 Volatility6.21% 8.31%
OptionableNo Debt/Eq0.00 EPS Q/Q24.20% Profit Margin- Rel Volume0.20 Prev Close1.56
ShortableYes LT Debt/Eq0.19 EarningsAug 06 AMC Payout- Avg Volume145.85K Price1.55
Recom- SMA20-8.01% SMA50-16.86% SMA200-48.77% Volume28,528 Change-0.64%
Jun-10-19 09:00AM  CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions GlobeNewswire +18.29%
Jun-05-19 09:00AM  CohBar to Hold 2019 Annual Shareholder Meeting and Investor Update June 18, 2019 GlobeNewswire -14.36%
May-29-19 09:00AM  CohBar to Present Data on Novel Analogs of a Mitochondrially Encoded Peptide with Beneficial Effects in an Animal Model of Type 2 Diabetes at the American Diabetes Association 79th Scientific Sessions GlobeNewswire
May-07-19 04:03PM  CohBar Reports First Quarter 2019 Financial Results and Business Update GlobeNewswire
03:00PM  CohBar, Inc. to Host Earnings Call ACCESSWIRE
09:00AM  CohBar Appoints Steven B. Engle as Chief Executive Officer GlobeNewswire
Apr-26-19 03:35PM  CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019 GlobeNewswire +5.93%
Apr-23-19 09:00AM  CohBar Announces Key Opinion Leader Conference Call and Webcast GlobeNewswire
Apr-22-19 09:00AM  CohBar Announces the Appointment of David Greenwood to its Board of Directors GlobeNewswire -7.50%
Mar-18-19 04:03PM  CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -8.68%
Mar-04-19 09:00AM  CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019 GlobeNewswire
Feb-11-19 09:00AM  CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors GlobeNewswire
Dec-10-18 04:05PM  CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer GlobeNewswire
Nov-29-18 08:40AM  Research Report Identifies Equinix, Universal Electronics, LHC Group, Cohbar, Amgen, and Aetna with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-26-18 09:00AM  CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation IPSEN Longevity Prize GlobeNewswire
Nov-14-18 04:03PM  CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire -11.17%
Nov-08-18 09:00AM  CohBar Co-Founder and Scientific Advisor Dr. David Sinclair Named as one of TIME Magazines Health Care 50 GlobeNewswire
Nov-05-18 09:00AM  CohBar Provides Update on CB4211 Clinical Trial GlobeNewswire -16.59%
Oct-31-18 09:00AM  CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018 GlobeNewswire
Oct-22-18 08:20AM  Recent Analysis Shows Renren, LiveXLive Media, Pivotal Software, Sun Life Financial, Gold Standard Ventures, and Cohbar Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-25-18 09:00AM  CohBar Engages LifeSci Advisors as Investor Relations Partner GlobeNewswire
Aug-14-18 04:03PM  CohBar Announces Second Quarter 2018 Financial Results GlobeNewswire
Aug-02-18 01:09PM  CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018 GlobeNewswire
Jul-12-18 09:00AM  CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH GlobeNewswire
Jun-27-18 04:05PM  CohBar Completes Sale of $20 Million Under Controlled Equity Offering GlobeNewswire
09:00AM  CohBar Added to Russell 2000® Index GlobeNewswire
Jun-25-18 12:08PM  CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions GlobeNewswire
Jun-07-18 08:59AM  CohBar Announces the Appointment of Dr. Philippe Calais to its Board GlobeNewswire
Jun-06-18 09:45AM  CohBar to Hold 2018 Annual Shareholder Meeting and Investor Update, June 19, 2018 GlobeNewswire +16.12%
May-29-18 09:00AM  CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions GlobeNewswire
May-15-18 04:03PM  CohBar, Inc. Announces First Quarter 2018 Financial Results GlobeNewswire
Apr-18-18 04:05PM  CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange GlobeNewswire
Apr-13-18 04:05PM  CohBar, Inc. Announces Closing of Private Placement for Aggregate Gross Proceeds of Approximately $3,900,000 GlobeNewswire +5.56%
Apr-02-18 04:03PM  CohBar, Inc. Announces Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-29-18 04:10PM  CohBar, Inc. Announces Closing of First Tranche of Private Placement GlobeNewswire
Mar-26-18 09:00AM  CohBar, Inc. Announces Financing of up to US$5,000,000 in Unsecured Promissory Notes GlobeNewswire
Mar-19-18 04:35PM  CohBar, Inc. to Announce 2017 Fourth Quarter Financial Results and Host Conference Call for Shareholders on April 2, 2018 GlobeNewswire
Jan-16-18 07:00AM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +16.15%
CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular disease, and neurodegenerative disease, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel optimized analog of the MOTS-c mitochondrial-derived peptide for the treatment of NASH and obesity. The company was founded in 2007 and is headquartered in Menlo Park, California.